Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron S Kesselheim

Showing results (1-10 of 858) with videos related to

Pageof 86
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
FDA regulatory pathways for expedited drug development and approvalAaron S Kesselheim
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
Variability in global drug pricesAaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 13, 2011
The backlash against bioequivalence and the interchangeability of brand-name and generic drugsAaron S Kesselheim
The New England Journal of Medicine|November 7, 2008
Drug development for neglected diseases - the trouble with FDA review vouchersAaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 15, 2011
Covert pharmaceutical promotion in free medical journalsAaron S Kesselheim
BMJ (Clinical Research Ed.)|February 22, 2013
Drug company gifts to medical students: the hidden curriculumAaron S Kesselheim
The Milbank Quarterly|September 22, 2011
An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequencesAaron S Kesselheim
The New England Journal of Medicine|November 5, 2010
Using market-exclusivity incentives to promote pharmaceutical innovationAaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
<b>Government Support of Meaningful Drug and Device Innovation:</b> Pathways and ChallengesAaron S Kesselheim
Plos Medicine|June 21, 2013
Rising health care costs and life-cycle management in the pharmaceutical marketAaron S Kesselheim
Pageof 86

Showing results (1-10 of 858) with videos related to

Sort By:
Pageof 86
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
FDA regulatory pathways for expedited drug development and approvalAaron S Kesselheim
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
Variability in global drug pricesAaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 13, 2011
The backlash against bioequivalence and the interchangeability of brand-name and generic drugsAaron S Kesselheim
The New England Journal of Medicine|November 7, 2008
Drug development for neglected diseases - the trouble with FDA review vouchersAaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 15, 2011
Covert pharmaceutical promotion in free medical journalsAaron S Kesselheim
BMJ (Clinical Research Ed.)|February 22, 2013
Drug company gifts to medical students: the hidden curriculumAaron S Kesselheim
The Milbank Quarterly|September 22, 2011
An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequencesAaron S Kesselheim
The New England Journal of Medicine|November 5, 2010
Using market-exclusivity incentives to promote pharmaceutical innovationAaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
<b>Government Support of Meaningful Drug and Device Innovation:</b> Pathways and ChallengesAaron S Kesselheim
Plos Medicine|June 21, 2013
Rising health care costs and life-cycle management in the pharmaceutical marketAaron S Kesselheim
Pageof 86